NYSTATIN - nystatin cream
Cosette Pharmaceuticals, Inc.

DESCRIPTION
Nystatin is a polyene antifungal antibiotic obtained from *Streptomyces nursei*.

Structural formula:

\[
\text{C}_{47}\text{H}_{75}\text{NO}_{17} \quad \text{Molecular Weight: 926.13}
\]

Nystatin Cream, USP is for dermatologic use.

Nystatin cream for topical use, contains 100,000 USP nystatin units per gram in a cream base containing aluminum hydroxide gel, ceteareth-15, glyceryl monostearate, polyethylene glycol 400 monostearate, propylene glycol, purified water, simethicone emulsion, sorbitol solution, titanium dioxide, white petrolatum, methylparaben, propylparaben, and sodium hydroxide.

CLINICAL PHARMACOLOGY

Pharmacokinetics
Nystatin is not absorbed from intact skin or mucous membrane.

Microbiology
Nystatin is an antibiotic which is both fungistatic and fungicidal *in vitro* against a wide variety of yeasts and yeast-like fungi, including *Candida albicans*, *C. parapsilosis*, *C. tropicalis*, *C. guilliermondi*, *C. pseudotropicalis*, *C. krusei*, *Torulopsis glabrata*, *Tricophyton rubrum*, *T. mentagrophytes*. Nystatin acts by binding to sterols in the cell membrane of susceptible species resulting in a change in membrane permeability and the subsequent leakage of intracellular components. On repeated subculturing with increasing levels of nystatin, *Candida albicans* does not develop resistance to nystatin. Generally, resistance to nystatin does not develop during therapy. However, other species of *Candida* (*C. tropicalis*, *C. guilliermondi*, *C. krusei*, and *C. stellatoides*) become quite resistant on treatment with nystatin and simultaneously become cross resistant to amphotericin as well. This resistance is lost when the antibiotic is removed. Nystatin exhibits no appreciable activity against bacteria, protozoa, or viruses.

INDICATIONS AND USAGE
Nystatin Cream, USP is indicated in the treatment of cutaneous or mucocutaneous mycotic infections caused by *Candida albicans* and other susceptible *Candida* species.
This cream is not indicated for systemic, oral, intravaginal or ophthalmic use.

CONTRAINDICATIONS
Nystatin cream is contraindicated in patients with a history of hypersensitivity to any of its components.

PRECAUTIONS
General

Nystatin cream should not be used for the treatment of systemic, oral, intravaginal or ophthalmic infections.

If irritation or sensitization develops, treatment should be discontinued and appropriate measures taken as indicated. It is recommended that KOH smears, cultures, or other diagnostic methods be used to confirm the diagnosis of cutaneous or mucocutaneous candidiasis and to rule out infection caused by other pathogens.

INFORMATION FOR THE PATIENT
Patients using this medication should receive the following information and instructions:

1. The patient should be instructed to use this medication as directed (including the replacement of missed doses). This medication is not for any disorder other than that for which it is prescribed.
2. Even if symptomatic relief occurs within the first few days of treatment, the patient should be advised not to interrupt or discontinue therapy until the prescribed course of treatment is completed.
3. If symptoms of irritation develop, the patient should be advised to notify the physician promptly.

Laboratory Tests
If there is a lack of therapeutic response, KOH smears, cultures or other diagnostic methods should be repeated.

Carcinogenesis, Mutagenesis, and Impairment of Fertility
No long-term animal studies have been performed to evaluate the carcinogenic potential of nystatin. No studies have been performed to determine the mutagenicity of nystatin or the effects on male or female fertility.

Pregnancy
Teratogenic Effects

Category C

Animal reproduction studies have not been conducted with any nystatin cream. It also is not known whether this cream can cause fetal harm when used by a pregnant woman or can affect reproductive capacity. Nystatin cream should be prescribed for a pregnant woman only if the potential benefit to the mother outweighs the potential risk to the fetus.

Nursing Mothers
It is not known whether nystatin is excreted in human milk. Caution should be exercised when nystatin is
prescribed for a nursing woman.

**Pediatric Use**

Safety and effectiveness have been established in the pediatric population from birth to 16 years. (See **DOSAGE AND ADMINISTRATION**.)

**Geriatric Use**

Clinical studies with nystatin cream did not include sufficient numbers of subjects aged 65 years and older to determine whether they respond differently than younger subjects. Other reported clinical experience has not identified differences in responses between elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

**ADVERSE REACTIONS**

The frequency of adverse events reported in patients using nystatin cream is less than 0.1%. The more common events that were reported include allergic reactions, burning, itching, rash, eczema, and pain on application.

(See **PRECAUTIONS: General**.)

To report SUSPECTED ADVERSE REACTIONS, contact G&W Laboratories, Inc. at 1-800-922-1038 or FDA at 1-800-FDA-1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch).

**DOSAGE AND ADMINISTRATION**

**Adults and Pediatric Patients (Neonates and Older)**

Apply liberally to affected areas twice daily or as indicated until healing is complete.

**HOW SUPPLIED**

Nystatin Cream, USP is a smooth yellow cream.

Nystatin Cream, USP is supplied in 15 g (NDC 0713-0678-15) and 30 g (NDC 0713-0678-31) tubes providing 100,000 USP Nystatin units per gram.

**Store at 20° to 25°C (68° to 77°F)** [see USP Controlled Room Temperature]. Avoid freezing.

**Manufactured by:**

G&W Laboratories, Inc.
111 Coolidge Street
South Plainfield, NJ 07080

Rev. 08/2015
8-0678GW2

**PRINCIPAL DISPLAY PANEL**
**Product Information**

<table>
<thead>
<tr>
<th>Product Type</th>
<th>HUMAN PRESCRIPTION DRUG</th>
<th>Item Code (Source)</th>
<th>NDC:0713-0678</th>
</tr>
</thead>
<tbody>
<tr>
<td>Route of Administration</td>
<td>TOPICAL</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Active Ingredient/Active Moiety**

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Basis of Strength</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nystatin (UNII: BDF1OIC72E) (Nystatin - UNII:BDF1OIC72E)</td>
<td>Nystatin</td>
<td>100000 [USP'U] in 1 g</td>
</tr>
</tbody>
</table>

**Inactive Ingredients**

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>Algeldrate (UNII: 03J1IKI03C)</td>
<td></td>
</tr>
<tr>
<td>Ceteareth-15 (UNII: 867H4YOZ8Z)</td>
<td></td>
</tr>
<tr>
<td>Glyceryl Monostearate (UNII: 230OU9XXE4)</td>
<td></td>
</tr>
<tr>
<td>Propylene Glycol (UNII: 6DC9Q167V3)</td>
<td></td>
</tr>
<tr>
<td>Water (UNII: 059QF0K0R)</td>
<td></td>
</tr>
<tr>
<td>Dimethicone (UNII: 92RU3N3YIO)</td>
<td></td>
</tr>
</tbody>
</table>
**Cosette Pharmaceuticals, Inc.**

**Sorbitol** (UNII: 506T60A25R)

**Titanium Dioxide** (UNII: 15FIX9V2JP)

**Petrolatum** (UNII: 4T6H2BN9U)

**Methylparaben** (UNII: A21B7H9T)

**Propylparaben** (UNII: ZB1X2SC1OH)

**Sodium Hydroxide** (UNII: 55X04QC32I)

**Polyethylene Glycol 400** (UNII: B697894SGQ)

### Product Characteristics

<table>
<thead>
<tr>
<th>Color</th>
<th>Shape</th>
<th>Flavor</th>
<th>Imprint Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>YELLOW</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Packaging

<table>
<thead>
<tr>
<th>#</th>
<th>Item Code</th>
<th>Package Description</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>NDC:0713-0678-15</td>
<td>1 in 1 CARTON</td>
<td>04/01/2015</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td></td>
<td>15 g in 1 TUBE; Type 0: Not a Combination Product</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>NDC:0713-0678-31</td>
<td>1 in 1 CARTON</td>
<td>04/01/2015</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td></td>
<td>30 g in 1 TUBE; Type 0: Not a Combination Product</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Marketing Information

<table>
<thead>
<tr>
<th>Marketing Category</th>
<th>Application Number or Monograph Citation</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>ANDA</td>
<td>ANDA061966</td>
<td>04/01/2015</td>
<td></td>
</tr>
</tbody>
</table>

**Labeler** - Cosette Pharmaceuticals, Inc. (116918230)

**Registrant** - Cosette Pharmaceuticals, Inc. (116918230)

**Establishment**

<table>
<thead>
<tr>
<th>Name</th>
<th>Address</th>
<th>ID/FEI</th>
<th>Business Operations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cosette Pharmaceuticals, Inc.</td>
<td></td>
<td>116918230</td>
<td>analysis(0713-0678) , label(0713-0678) , manufacture(0713-0678) , pack(0713-0678)</td>
</tr>
</tbody>
</table>

Revised: 12/2019